Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2017 call → NOWe need answer YES/NO based on transcript. Need determine if management describes company currently living through defined waiting period paying out of pocket, benefit not arrived, end specific near-dated event, working toward it. Need identify one coherent situation. Transcript: Company Insmed, developing ALIS for NTM lung disease. Phase III positive, NDA filing by end March, potential US launch before end 2018. Precommercial activities: hired therapeutic specialists, key account directors, building patient support infrastructure, producing commercial batches, third-party manufacturing site. They are spending on precommercial planning, manufacturing, etc. They have not yet launched product, no revenue. They are paying costs now for future launch. End is potential US launch before end 2018. Is that a defined waiting period? Management describes precommercial activities, hiring field team, training, deploying mid-March, building infrastructure midyear, dry runs, producing commercial batches. They are incurring expenses now for launch. They expect approval and launch. This seems like company bearing cost of pre-launch buildout with benefit not yet arrived. The far side is launch before end 2018, specific near-dated. They are working toward it. Is it "paying now for something not yet earning"? Yes, precommercial expenses, manufacturing batches, headcount. Management speaks as main current work? Yes, they emphasize transition to commercial organization, precommercial activities. Not apologizing. Far side specific? Potential US launch before end 2018, NDA filing by end March, priority review, AdCom. But approval is not guaranteed; however they are preparing. The question says arrival should depend chiefly on work already in motion and resources already committed rather than something company still has to win, raise, or be granted. Here launch depends on FDA approval, which is a regulatory decision not yet granted. But management is confident, filing NDA. Is that "granted"? The question says "securing approvals" is NO if end depends on winning demand, obtaining financing, securing approvals, or decisions not yet made. So if the far side is launch contingent on FDA approval, that is a decision not yet made. However management says "potential US launch" and "we believe well on our way". But the waiting period is precommercial buildout; the benefit is launch.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.